1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Haemophilus Influenzae Infections - Pipeline Review, H2 2013

Haemophilus Influenzae Infections - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 58 pages

Haemophilus Influenzae Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Haemophilus Influenzae Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Haemophilus Influenzae Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Haemophilus Influenzae Infections. Haemophilus Influenzae Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Haemophilus Influenzae Infections.
- A review of the Haemophilus Influenzae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Haemophilus Influenzae Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Haemophilus Influenzae Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Haemophilus Influenzae Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Haemophilus Influenzae Infections - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Haemophilus Influenzae Infections Overview 7
Therapeutics Development 8
Pipeline Products for Haemophilus Influenzae Infections - Overview 8
Pipeline Products for Haemophilus Influenzae Infections - Comparative Analysis 9
Haemophilus Influenzae Infections - Therapeutics under Development by Companies 10
Haemophilus Influenzae Infections - Therapeutics under Investigation by Universities/Institutes 12
Haemophilus Influenzae Infections - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Haemophilus Influenzae Infections - Products under Development by Companies 16
Haemophilus Influenzae Infections - Products under Investigation by Universities/Institutes 17
Haemophilus Influenzae Infections - Companies Involved in Therapeutics Development 18
Sanofi 18
AstraZeneca PLC 19
GlaxoSmithKline plc 20
Daiichi Sankyo Company, Limited 21
Dainippon Sumitomo Pharma Co., Ltd. 22
Wockhardt Limited 23
Panacea Biotec Limited 24
Haemophilus Influenzae Infections - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Assessment by Therapeutic Class 34
Drug Profiles 36
Act-HIB reconstituted with TRIPACEL - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
GSK-2189242A - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
GSK-2838500A - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
GSK-2838497A - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
GSK-2838501A - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Second Generation Ketolides - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
SM-295291 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
SM-369926 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Human Beta-Defensin-3 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Compound-G1 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Pyrrolamide-4 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Haemophilus Influenzae Infections - Recent Pipeline Updates 49
Haemophilus Influenzae Infections - Dormant Projects 51
Haemophilus Influenzae Infections - Product Development Milestones 52
Featured News and Press Releases 52
Sep 27, 2013: US FDA warns Pfizer's drug Tygacil raises risk of death 52
Mar 25, 2013: Viscogel Demonstrates Proof-of-Concept In A Phase I/II Clinical Trial 52
Dec 19, 2011: Viscogel Announces Publication Of Preclinical Results Of ViscoGel 53
Jun 15, 2011: Takeda To Initiate TAK-816 Phase III Clinical Trial In Japan 53
Jul 30, 2010: Sanofi Pasteur to acquire all shares of Joint Venture with Daiichi-Sankyo in Japan 54
Nov 10, 2008: Sanofi Pasteur First International Vaccine Company to Enter Japan with Pediatric vaccine 54
Sep 27, 1996: FDA approval of a Haemophilus b Conjugate Vaccine combined by reconstitution with an acellular pertussis vaccine 55
Jun 24, 1996: Connaught applies to FDA for licensing of first acellular pertussis vaccine to be used in combination with hib vaccine for infants 55
Apr 23, 1993: Sanofi Receives FDA Approval For New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine ActHIB for Infants and Children 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58



List of Tables

Number of Products under Development for Haemophilus Influenzae Infections, H2 2013 8
Number of Products under Development for Haemophilus Influenzae Infections - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Late Stage Development, H2 2013 13
Comparative Analysis by Clinical Stage Development, H2 2013 14
Comparative Analysis by Early Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
Haemophilus Influenzae Infections - Pipeline by Sanofi, H2 2013 18
Haemophilus Influenzae Infections - Pipeline by AstraZeneca PLC, H2 2013 19
Haemophilus Influenzae Infections - Pipeline by GlaxoSmithKline plc, H2 2013 20
Haemophilus Influenzae Infections - Pipeline by Daiichi Sankyo Company, Limited, H2 2013 21
Haemophilus Influenzae Infections - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H2 2013 22
Haemophilus Influenzae Infections - Pipeline by Wockhardt Limited, H2 2013 23
Haemophilus Influenzae Infections - Pipeline by Panacea Biotec Limited, H2 2013 24
Assessment by Monotherapy Products, H2 2013 25
Number of Products by Stage and Target, H2 2013 27
Number of Products by Stage and Mechanism of Action, H2 2013 29
Number of Products by Stage and Route of Administration, H2 2013 31
Number of Products by Stage and Molecule Type, H2 2013 33
Number of Products by Stage and Therapeutic Class, H2 2013 35
Haemophilus Influenzae Infections Therapeutics - Recent Pipeline Updates, H2 2013 49
Haemophilus Influenzae Infections - Dormant Projects, H2 2013 51



List of Figures

Number of Products under Development for Haemophilus Influenzae Infections, H2 2013 8
Number of Products under Development for Haemophilus Influenzae Infections - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 14
Comparative Analysis by Early Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 25
Number of Products by Top 10 Target, H2 2013 26
Number of Products by Stage and Top 10 Target, H2 2013 27
Number of Products by Top 10 Mechanism of Action, H2 2013 28
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 29
Number of Products by Top 10 Route of Administration, H2 2013 30
Number of Products by Stage and Top 10 Route of Administration, H2 2013 31
Number of Products by Top 10 Molecule Type, H2 2013 32
Number of Products by Stage and Top 10 Molecule Type, H2 2013 33
Number of Products by Top 10 Therapeutic Class, H2 2013 34
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 35



Companies Mentioned

Sanofi
AstraZeneca PLC
GlaxoSmithKline plc
Daiichi Sankyo Company, Limited
Dainippon Sumitomo Pharma Co., Ltd.
Wockhardt Limited
Panacea Biotec Limited

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) ...

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...


Download Unlimited Documents from Trusted Public Sources

Healthcare Industry - Analyst Report, December 2016

  • December 2016
    15 pages
  • Hepatitis C  

  • India  

    World  

View report >

GSK - Company Report, November 2016

  • November 2016
    90 pages
  • Vaccine  

    Infectious Dise...  

  • World  

    United Kingdom  

    Europe  

View report >

GSK - Company Report, November 2016

  • November 2016
    90 pages
  • Vaccine  

    Infectious Dise...  

  • World  

    United Kingdom  

    Europe  

View report >

Related Market Segments :

Infectious Disease

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.